Ocular Therapeutix (OCUL)

• Market cap: $2.16B
• 1 day: -2.25%
• 5 days: -7.88%
• 1 month: -1.22%
• 3 months: 46.51%
• 6 months: 53.15%
• Year to date: 39.13%
• 1 year: 38.81%
• 5 years: 37.4%
• 10 years: -35.15%
• Sector: Healthcare
• Industry: Biotechnology

About: Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Employees: 274

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

137% more call options, than puts

Call options by funds: $9.7M | Put options by funds: $4.1M

56% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 48

44% more capital invested

Capital invested by funds: $1.01B [Q1] → $1.45B (+$446M) [Q2]

12.15% more ownership

Funds ownership: 86.38% [Q1] → 98.54% (+12.15%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 10 [Q1] → 10 (+0) [Q2]

6% less funds holding

Funds holding: 196 [Q1] → 184 (-12) [Q2]

29% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 31

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $15
• Avg. target: $18.67
• High target: $21

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Chardan Capital Daniil Gataulin	$21	Buy Initiated	15 Sep 2025
Scotiabank Greg Harrison	$20	Sector Outperform Maintained	6 Aug 2025
Needham Serge Belanger	$15	Buy Maintained	5 Aug 2025